Mirati Therapeutics (MRTX) PT Raised to $176 at BMO Capital
Tweet Send to a Friend
BMO Capital analyst George Farmer raised the price target on Mirati Therapeutics (NASDAQ: MRTX) to $176.00 (from $101.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
